NAS:RXRX (USA)
Â
Class A
$
5.21
+0.090 (+1.76%)
08:08 PM EST
Business Description
Recursion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US75629V1044
Share Class Description:
RXRX: Class ACompare
Compare
Traded in other countries / regions
RXRX.USARXRX.Mexico Index Membership
Russell 2000Russell 3000 IPO Date
2021-04-16Description
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.39 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 0.71 | |||||
| Beneish M-Score | 9.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 38.6 | |||||
| 3-Year EBITDA Growth Rate | -3.7 | |||||
| 3-Year EPS without NRI Growth Rate | -4.5 | |||||
| 3-Year FCF Growth Rate | 4.7 | |||||
| 3-Year Book Growth Rate | -6.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.71 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 53.82 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.43 | |||||
| 9-Day RSI | 52.71 | |||||
| 14-Day RSI | 52.5 | |||||
| 3-1 Month Momentum % | -17.39 | |||||
| 6-1 Month Momentum % | -39.39 | |||||
| 12-1 Month Momentum % | -38.97 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.11 | |||||
| Quick Ratio | 4.11 | |||||
| Cash Ratio | 3.52 | |||||
| Days Payable | 75.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -32.5 | |||||
| Shareholder Yield % | -17.52 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 6.54 | |||||
| Operating Margin % | -959.68 | |||||
| Net Margin % | -960.92 | |||||
| EBITDA Margin % | -877.33 | |||||
| FCF Margin % | -670.49 | |||||
| ROE % | -82.61 | |||||
| ROA % | -59.7 | |||||
| ROIC % | -110.58 | |||||
| 3-Year ROIIC % | -38.31 | |||||
| ROC (Joel Greenblatt) % | -327.3 | |||||
| ROCE % | -67.99 | |||||
| Moat score | 4 | |||||
| Tariff score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 26.05 | |||||
| PB Ratio | 2.27 | |||||
| Price-to-Tangible-Book | 4.82 | |||||
| EV-to-EBIT | -2.92 | |||||
| EV-to-EBITDA | -3.19 | |||||
| EV-to-Revenue | 27.98 | |||||
| EV-to-FCF | -4.17 | |||||
| Price-to-GF-Value | 0.68 | |||||
| Price-to-Net-Current-Asset-Value | 10.02 | |||||
| Price-to-Net-Cash | 16.28 | |||||
| Earnings Yield (Greenblatt) % | -34.25 | |||||
| FCF Yield % | -18.94 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers